ACETO Corp Increases Dividend by 8%
Fourth-Quarter Earnings Plunge 50% on Competition
ACETO Corporation (NASDAQ:ACET) announced today that its board of directors has approved an eight percent increase in its regular quarterly dividend. The new dividend payout of $0.065 per common share will be distributed on September 20, 2016 to shareholders of record as of September 9. (Source: “ACETO Board of Directors Increases Quarterly Cash Dividend by 8.3%,” ACETO Corporation, August 25, 2016).
Port Washington, New York-based ACETO has operations in 10 countries and is engaged in the development, marketing, sale and distribution of health products, pharmaceutical ingredients, and performance chemicals.
The increase in quarterly cash dividend was announced despite the company reporting that net income plunged 50% in the fourth quarter to $6.8 million, a decline from $13.6 million a year ago. The firm also registered an eight-percent decline in its sales in the fourth quarter to $135.4 million, from $147 million the year prior. (Source: “Aceto Corporation: ACETO Reports Fiscal 2016 Fourth Quarter and Record Full Year Results,” ACETO Corporation, August 25, 2016.)
This decline in sales reflects an, “intensified competition in our Rising Pharmaceutical business, an unfavorable comparison to exceptionally strong results last year that included a $9.5-million favorable sales adjustment at Rising and a $3.5-million earn-out adjustment, also at Rising,” said Sal Guccione, chief executive officer of ACETO, in the company’s earnings statement.
ACETO’s shares plunged 20% in New York trading today, almost wiping out all the gains of the past 12 months after the announcement of earnings. Shares were trading at $20.59 during early afternoon trading. In the fourth quarter, the gross margin also dropped drastically, by 17.3% to $34.0 million. (Source: Ibid.)
For fiscal 2017 earnings guidance, the company expects both sales and non-generally accepted accounting principles (GAAP) adjusted earnings per share (EPS) to grow in the mid-single digit percentage range, with GAAP EPS growing at a somewhat slower rate, the company said.
For 2017, the company is forecasting a reversal where both sales and net income will grow on the back of 12 to 15 new product launches for generics.
“Given the dynamics of our product launch schedule, we expect the second half performance to be stronger than the first half,” Guccione said. “The positive impact of these launches is expected to generate volume growth and accumulate over the course of fiscal 2017.” (Source: Ibid.)
Dear Reader: There is no magic formula to getting rich. Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis. We are 100% independent in that we are not affiliated with any bank or brokerage house. Information contained herein, while believed to be correct, is not guaranteed as accurate. Warning: Investing often involves high risks and you can lose a lot of money. Please do not invest with money you cannot afford to lose. The opinions in this content are just that, opinions of the authors. We are a publishing company and the opinions, comments, stories, reports, advertisements and articles we publish are for informational and educational purposes only; nothing herein should be considered personalized investment advice. Before you make any investment, check with your investment professional (advisor). We urge our readers to review the financial statements and prospectus of any company they are interested in. We are not responsible for any damages or losses arising from the use of any information herein. Past performance is not a guarantee of future results. All registered trademarks are the property of their respective owners
Sign up to receive our FREE Income Investors newsletter along with our special offers and get our FREE report:
5 Dividend Stocks to Own Forever
This is an entirely free service. No credit card required. You can opt-out at anytime.
We hate spam as much as you do.